{"page":{"totalFilteredElements":84},"studies":[{"active":true,"description":"A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients With Relapsed or Refractory Multiple Myeloma","eudractNumber":"2023-508590-89-00","id":9058,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06106945","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-01-16T09:53:56+01:00","shortTitle":"D7230C00001","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)","eudractNumber":"2023-505789-27-00","id":9783,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06526793","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-04-23T14:08:33+02:00","shortTitle":"D7404C00001 Soundtrack B","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the \nSafety and Efficacy of AZD0486 Monotherapy or in Combination with \nOther Anticancer Agents in Participants with Mature B-Cell Malignancies","eudractNumber":"2024-515034-33","id":10004,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-05-21T11:39:54+02:00","shortTitle":"D7407C00001 Soundtrack E","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Modular Phase I/II Open-label Dose Escalation and Dose \nExpansion Study to Evaluate the Safety, Pharmacokinetics, \nPharmacodynamics, and Efficacy of AZD5492, a T cell-engaging \nAntibody Targeting CD20 in Subjects with Relapsed or Refractory \nB-Cell Malignancies (TITANium)&#160;","eudractNumber":"2024-511099-34-00","id":10005,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT06542250","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-01-14T15:09:54+01:00","shortTitle":"D9960C00001 TITANium","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"Phase 3, Randomized, Open-Label Study of Belentamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnose Multiple Myeloma who are inelegible for ASCT<br />","eudractNumber":"2024-516030-35-00","id":10407,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-06T08:42:39+02:00","shortTitle":"DREAMM-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Lenalidomide, Adriamycin, Dexamethasone \n(RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction\n in Newly Diagnosed Multiple Myeloma Followed by Response-adapted \nConsolidation and Lenalidomide Maintance &#8211; A Randomized Multicenter \nPhase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)","eudractNumber":"2009-016616-21","id":414,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT01685814","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2012-07-20T12:37:36+02:00","shortTitle":"DSMM XIV","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<b>GMMG HD9/ DSMM XVIII:</b> A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.","eudractNumber":"2023-507402-13","id":9091,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06216158","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-03T13:12:13+02:00","shortTitle":"DSMM XVIII [GMMG HD9]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with</div><div>Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as</div><div>Induction Therapy and Teclistamab in Combination with Daratumumab and</div><div>Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-001186-12","id":8497,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05695508","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-12-01T15:24:49+01:00","shortTitle":"DSMM XX [GMMG-HD10], MajesTEC-5","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":4372,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-04-06T10:55:50+02:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL- FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":7900,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-04T15:27:44+01:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL-FL Register","therapeutical":false,"therapyLines":[]}]}